Navigation Links
Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study
Date:2/11/2008

'The Diabetes Educator' published study showing Medifast's effectiveness in

patients with type 2 diabetes

OWINGS MILLS, Md., Feb. 11 /PRNewswire-FirstCall/ -- Medifast, Inc. (NYSE: MED) today announced that a study conducted by researchers at the Johns Hopkins University Bloomberg School of Public Health, showing the Medifast Program outperforms the American Diabetes Association (ADA) recommended diet for patients with type 2 diabetes, has been published in the January/February issue of 'The Diabetes Educator'. The peer-reviewed journal is the official journal of the American Association of Diabetes Educators.

The examiner of the study from Johns Hopkins University submitted the study and informed Medifast that the study has been published in the most appropriate venue to help train diabetes educators about the effectiveness of Medifast Meal Replacements in the treatment of type 2 diabetes. The study was finalized for publication within the last 12 months after being presented to physicians and scholars attending the American Diabetes Association Convention in 2005.

"This study is one of many that validate the efficacy of Medifast Meal Replacements in the clinical setting," said Brad MacDonald, Chairman of the Board, Medifast, Inc. "Medifast continues to invest in the research and development of its products and programs to ensure that our claims to consumers are the most documented and credible in the industry."

In the study, the Medifast Program outperformed the ADA recommended diet in weight loss, adherence and biochemical outcomes. These findings suggest a re-evaluation of the ADA recommendation, which currently does not promote portion-controlled meal replacement programs in weight loss and weight maintenance for individuals with diabetes, is warranted. The study can be found at http://www.medifast1.com/weightloss/diabetes_study.asp

The results of the study also suggest that meal replacements may achieve the same outcomes in diabetics as bariatric surgery (though over the longer term), while mitigating the increased risk of morbidity and mortality associated with these more dangerous treatment approaches.

"A close friend of mine had some serious complications because of type 2 diabetes and it scared me to death," said Medifast client Steven Eldridge, of Raytown, MO. "I was suffering from the disease myself and decided to consult my doctor. He said the best thing I could do is to lose the weight, and that's when I found Medifast. I lost 114 pounds in 5 months on the Medifast Program and am totally off my diabetes medication for the first time in 6 years, which is an absolute miracle, and I have Medifast to thank!"

The study compared Medifast's effectiveness for weight control in people with type 2 diabetes to the standard ADA recommended dietary guidelines. The study enlisted 112 overweight or obese people with type 2 diabetes using two weight loss approaches of equal caloric prescription - the Medifast Program and a traditional reduced-calorie diet based on the ADA recommended dietary guidelines.

According to the results, participants randomized to receive Medifast lost twice as much weight and were twice as compliant with the diet as participants following the standard ADA diet. Approximately 40 percent of the Medifast participants lost greater than 5 percent of their initial weight, compared with 12 percent of those on the standard ADA diet. Additionally, 24 percent of the Medifast users decreased or eliminated their diabetes medication, compared to 0 percent on the standard ADA diet.

"We know that people with type 2 diabetes have a harder time losing weight than people without diabetes; thus, finding an approach that works better than other approaches is important," says Lawrence Cheskin, M.D. F.A.C.P., director of the Johns Hopkins Weight Management Center and principal investigator of the study. "This controlled study found that a diet using portion-controlled meal replacements yielded better weight control and compliance in obese people with diabetes than prescribing standard ADA dietary recommendations."

Medifast will continually participate in studies in the future, which will add even more credibility to the Medifast Brand and Programs. For more than 25 years Medifast has been prescribed by practitioners as a safe and effective program that yields significant results and has been proven to provide significant weight loss of 2-5 pounds per week.

"Over 15,000 physicians have recommended Medifast since 1980 and millions of consumers have realized the health and wellness benefit of our program," says Michael S. McDevitt, Chief Executive Officer, Medifast, Inc. "The publication of this study adds to Medifast's already stellar reputation in the medical community."

MED-G

About Medifast:

Medifast (NYSE: MED) is the leading easy-to-use, clinically proven portion-controlled weight loss program. Medifast has been recommended by 15,000 physicians and used by over one million customers. It is committed to enriching lives by providing innovative choices for lasting health. Medifast programs have been proven effective through studies by major university teaching hospitals. The company sells its products and programs via four unique distribution channels: 1) the web and national call centers, 2) national network of physicians, 3) medically supervised Medifast Weight Control Centers and 4) the Take Shape For Life direct-selling division, a network of health coaches. Medifast was founded in 1980 and is located in Owings Mills, Maryland. For more information log onto http://www.ChooseMedifast.com.

Please Note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Medifast believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Medifast's inability to attract and retain independent Associates and Members, stability in the pricing of print, TV and Direct Mail marketing initiatives affecting the cost to acquire customers, increases in competition, litigation, regulatory changes, and its planned growth into new domestic and international markets and new channels of distribution. Although Medifast's believes that the expectations, statements, and assumptions reflected in these forward- looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.


'/>"/>
SOURCE Medifast, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Medifast, Inc. Announces Acceptance for Publication of Clinical Efficacy Study
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Aspirin Named 8th World Wonder by Majority of Americans
6. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
7. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
8. TrialCheck(R) Cancer Clinical Trial Matching Interface to Debut on American Cancer Society Web Site
9. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
10. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
11. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
(Date:6/24/2016)... ... ... recruitment firm Slone Partners is pleased to announce the placement of Suzanne ... of North American Capital Sales at HTG Molecular . , In ... commercialization of the HTG EdgeSeq system and associated reagents in North America. , Headquartered ...
Breaking Medicine News(10 mins):